In this briefing:
- Shimadzu (7701 JP): 3Q Results Suggest a Trading Range
- Olympus: 3QFY03/19 Profits Decline on the Back of Litigation Related Costs
1. Shimadzu (7701 JP): 3Q Results Suggest a Trading Range
Shimadzu’s 3Q results were good enough to reassure long-term investors, but not good enough to be called a buy signal. Sales and operating profit were up 4.5% and 4.6% year-on-year, respectively, in the three months to December, an improvement over 2Q but well below the double-digit increases recorded in 1Q and last fiscal year. Forex losses and other factors led to a 2.2% decline in net profit.
Sales were up in Japan, Europe and Asia ex-Japan and ex-China, but down in America, China and Other Regions. Sales of core Analytical & Measuring Instruments were up 2.4%, operating profit on those sales was up 4.1% and the operating margin rose to +15.4% from +15.1% the previous year.
Sales of Industrial Machinery were down 5.7%, but operating profit on those sales was up 2.7% and the division generated a +9.7% operating margin vs. +9.0% the previous year. Sales of turbo-molecular pumps, primarily to semiconductor equipment makers, were down 14.3%.
Medical System sales were up 10.6% and the division generated a +1.5% operating margin vs. + 0.1% the previous year. Aircraft Equipment sales were up 12.1% but the division made a -0.5% operating loss vs. +1.2% profit the previous year.
At ¥2,659 (Friday, February 8 closing price), the shares are selling at 24x our EPS estimate for FY Mar-19 and 12x EV/EBITDA. The five-year historical P/E range is 13x – 30x, the EV/EBITDA range is 6x – 16x. Over the next several quarters, we expect continued weakness in Industrial Machinery to offset single-digit growth in Instruments, keeping overall growth low.
2. Olympus: 3QFY03/19 Profits Decline on the Back of Litigation Related Costs
Olympus Corporation (7733 JP) reported its 3QFY03/19 results on Friday (08th February) after markets closed. The third quarter revenue dropped 1.7% YoY while operating profit declined by a significant 21.5% YoY, which was 12% below consensus estimates. The operating profit margin for the quarter was 8.8% compared to 11.1% for the same period last year.
Revenue and Operating Profit Fell Below Consensus Estimates for 3QFY03/19
JPY (bn) | 3QFY03/18 | 3QFY03/19 | YoY Change | Consensus | Company Vs. Consensus |
Revenue | 202.6 | 199.2 | -1.7% | 201.6 | -1.2% |
Operating Profit | 22.4 | 17.6 | -21.5% | 20.0 | -12.0% |
OPM | 11.1% | 8.8% |
|
|
|
The cumulative nine-month results were not impressive either. Although revenue saw a marginal improvement of 1.6% YoY, operating profit declined by 66%, resulting in a 700 basis point decline in operating margin, which fell to just 3.5%. Revenue and operating profit missed consensus estimates by 0.4% and 10.4%, respectively.
Operating Profit for 9MFY03/19 Declined by More than Half Compared to a Year Ago
JPY (bn) | 9MFY03/18 | 9MFY03/19 | YoY Change | Consensus | Company Vs. Consensus |
Revenue | 572.1 | 581.0 | 1.6% | 583.4 | -0.4% |
Operating Profit | 59.8 | 20.6 | -65.6% | 23.0 | -10.4% |
OPM | 10.5% | 3.5% |
|
|
|
The company shares are currently trading at JPY4,645 per share which we believe is overvalued based on our EV/EBIT valuation. The premium is not justified given the governance related issues and the scandals currently faced by the company. Further, Olympus’ financial performance has been disappointing recently, and the company’s largest segment is growing only at single-digits and the Imaging business continues to drag on company revenue and margins. The share price gained nearly 38% since the beginning of the year following the company’s announcement to transform its business and improve governance. In our view the potential for a transformation in governance and business practices is already fully-discounted in the share price.
Get Straight to the Source on Smartkarma
Smartkarma supports the world’s leading investors with high-quality, timely, and actionable Insights. Subscribe now for unlimited access, or request a demo below.